• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

芳烃受体(AhR)和芳烃受体核转运蛋白(ARNT)在胎儿、良性增生性和恶性前列腺组织中的表达

Expression of the aryl hydrocarbon receptor (AhR) and the aryl hydrocarbon receptor nuclear translocator (ARNT) in fetal, benign hyperplastic, and malignant prostate.

作者信息

Kashani M, Steiner G, Haitel A, Schaufler K, Thalhammer T, Amann G, Kramer G, Marberger M, Schöller A

机构信息

Department of Urology, University of Vienna, Austria.

出版信息

Prostate. 1998 Oct 1;37(2):98-108. doi: 10.1002/(sici)1097-0045(19981001)37:2<98::aid-pros6>3.0.co;2-h.

DOI:10.1002/(sici)1097-0045(19981001)37:2<98::aid-pros6>3.0.co;2-h
PMID:9759704
Abstract

BACKGROUND

Androgen-dependent tissue has been reported to be affected by chemical ligands of the aryl hydrocarbon receptor (AhR), a ligand-activated transcription factor, which heterodimerizes with the aryl hydrocarbon receptor nuclear translocator protein (ARNT).

METHODS

Fetal (n = 3), benign hyperplastic (BPH) (n = 10), and carcinomatous (CaP) (n = 19) prostate tissues were analyzed using immunohistochemistry. Western blot analysis was used to confirm the identity of the recognized proteins.

RESULTS

Immunoblotting of enriched prostatic epithelial cells (EC) and stromal cells revealed constitutive expression of bands at around 110 kDa and 90 kDa, using anti-AhR and anti-ARNT, respectively. Immunohistology of the fetal specimens revealed heterogeneous cytoplasmic and nuclear AhR expression of immature EC and mesenchymal cells. Constitutive expression of AhR (primarily cytoplasmic) and ARNT (nuclear and cytoplasmic) by the majority of adult basal and secretory EC, CaP, and smooth muscle cells was confirmed in situ. The most intense anti-AhR/-ARNT reactivity was found on smooth muscle cells, followed by EC and fibrocytes. Secretory BPH-EC revealed significantly decreased AhR expression when compared to normal tissue segments. By contrast, anti-AhR reactivity was frequently increased in the more dedifferentiated tumor areas.

CONCLUSIONS

These findings suggest that an undefined physiologic AhR ligand(s) as well as environmental factors may exert effects on EC and smooth muscle cells in the prostate through binding to these receptors.

摘要

背景

据报道,雄激素依赖组织会受到芳烃受体(AhR)化学配体的影响,AhR是一种配体激活的转录因子,它与芳烃受体核转运蛋白(ARNT)形成异二聚体。

方法

采用免疫组织化学方法分析胎儿(n = 3)、良性增生(BPH)(n = 10)和癌性(CaP)(n = 19)前列腺组织。蛋白质免疫印迹分析用于确认所识别蛋白质的身份。

结果

分别使用抗AhR和抗ARNT对富集的前列腺上皮细胞(EC)和基质细胞进行免疫印迹分析,结果显示在约110 kDa和90 kDa处有组成性条带表达。胎儿标本的免疫组织学显示未成熟EC和间充质细胞的AhR在细胞质和细胞核中表达不均一。通过原位分析证实,大多数成年基底和分泌性EC、CaP以及平滑肌细胞组成性表达AhR(主要在细胞质中)和ARNT(在细胞核和细胞质中)。在平滑肌细胞上发现最强的抗AhR/-ARNT反应性,其次是EC和纤维细胞。与正常组织段相比,分泌性BPH-EC显示AhR表达显著降低。相比之下,在分化程度更高的肿瘤区域,抗AhR反应性经常增加。

结论

这些发现表明,一种未明确的生理性AhR配体以及环境因素可能通过与这些受体结合,对前列腺中的EC和平滑肌细胞产生影响。

相似文献

1
Expression of the aryl hydrocarbon receptor (AhR) and the aryl hydrocarbon receptor nuclear translocator (ARNT) in fetal, benign hyperplastic, and malignant prostate.芳烃受体(AhR)和芳烃受体核转运蛋白(ARNT)在胎儿、良性增生性和恶性前列腺组织中的表达
Prostate. 1998 Oct 1;37(2):98-108. doi: 10.1002/(sici)1097-0045(19981001)37:2<98::aid-pros6>3.0.co;2-h.
2
The aryl hydrocarbon receptor and aryl hydrocarbon receptor nuclear translocator protein show distinct subcellular localizations in Hepa 1c1c7 cells by immunofluorescence microscopy.通过免疫荧光显微镜观察,芳烃受体和芳烃受体核转运蛋白在Hepa 1c1c7细胞中显示出不同的亚细胞定位。
Mol Pharmacol. 1994 Mar;45(3):428-38.
3
Determination of aryl hydrocarbon receptor nuclear translocator protein concentration and subcellular localization in hepatic and nonhepatic cell culture lines: development of quantitative Western blotting protocols for calculation of aryl hydrocarbon receptor and aryl hydrocarbon receptor nuclear translocator protein in total cell lysates.肝和非肝细胞系中芳烃受体核转运蛋白浓度及亚细胞定位的测定:用于计算总细胞裂解物中芳烃受体和芳烃受体核转运蛋白的定量蛋白质免疫印迹法方案的建立。
Mol Pharmacol. 1997 Aug;52(2):202-11. doi: 10.1124/mol.52.2.202.
4
Trans-activation by the human aryl hydrocarbon receptor and aryl hydrocarbon receptor nuclear translocator proteins: direct interactions with basal transcription factors.人芳烃受体和芳烃受体核转运蛋白的反式激活:与基础转录因子的直接相互作用。
Mol Pharmacol. 1996 Sep;50(3):538-48.
5
Developmental expression of two members of a new class of transcription factors: II. Expression of aryl hydrocarbon receptor nuclear translocator in the C57BL/6N mouse embryo.一类新的转录因子中两个成员的发育表达:II. C57BL/6N小鼠胚胎中芳烃受体核转运蛋白的表达
Dev Dyn. 1995 Oct;204(2):144-55. doi: 10.1002/aja.1002040205.
6
Uterine and ovarian aryl hydrocarbon receptor (AHR) and aryl hydrocarbon receptor nuclear translocator (ARNT) mRNA expression in benign and malignant gynaecological conditions.子宫和卵巢芳烃受体(AHR)及芳烃受体核转运蛋白(ARNT)mRNA在良性和恶性妇科疾病中的表达
Mol Hum Reprod. 2002 Jan;8(1):75-80. doi: 10.1093/molehr/8.1.75.
7
Regulation of constitutive gene expression through interactions of Sp1 protein with the nuclear aryl hydrocarbon receptor complex.通过Sp1蛋白与核芳烃受体复合物的相互作用对组成型基因表达的调控。
Biochemistry. 1999 Aug 31;38(35):11490-500. doi: 10.1021/bi982578f.
8
Analysis of aryl hydrocarbon receptor-mediated signaling during physiological hypoxia reveals lack of competition for the aryl hydrocarbon nuclear translocator transcription factor.生理性缺氧期间芳烃受体介导信号传导的分析揭示芳烃核转运蛋白转录因子不存在竞争。
Mol Pharmacol. 1999 Dec;56(6):1127-37. doi: 10.1124/mol.56.6.1127.
9
Functional analysis of aryl hydrocarbon receptor nuclear translocator interactions with aryl hydrocarbon receptor in the yeast two-hybrid system.酵母双杂交系统中芳烃受体核转运蛋白与芳烃受体相互作用的功能分析。
Biochem Pharmacol. 1995 Oct 12;50(8):1295-302. doi: 10.1016/0006-2952(95)02016-6.
10
Identification of functional aryl hydrocarbon receptor and aryl hydrocarbon receptor nuclear translocator in murine splenocytes.小鼠脾细胞中功能性芳烃受体和芳烃受体核转运蛋白的鉴定
Biochem Pharmacol. 1996 Sep 13;52(5):771-80. doi: 10.1016/0006-2952(96)00360-7.

引用本文的文献

1
Aryl hydrocarbon receptor as a drug target in advanced prostate cancer therapy - obstacles and perspectives.芳烃受体作为晚期前列腺癌治疗中的药物靶点——障碍与前景
Transcription. 2025 Feb;16(1):47-66. doi: 10.1080/21541264.2024.2334106. Epub 2024 Mar 28.
2
The aryl hydrocarbon receptor is constitutively active in advanced prostate cancer cells.芳烃受体在晚期前列腺癌细胞中具有组成性活性。
PLoS One. 2014 Apr 22;9(4):e95058. doi: 10.1371/journal.pone.0095058. eCollection 2014.
3
Potential protective mechanisms of aryl hydrocarbon receptor (AHR) signaling in benign prostatic hyperplasia.
芳香烃受体(AHR)信号在良性前列腺增生中的潜在保护机制。
Differentiation. 2011 Nov-Dec;82(4-5):211-9. doi: 10.1016/j.diff.2011.05.011.
4
AHR signaling in prostate growth, morphogenesis, and disease.芳香烃受体信号传导在前列腺生长、形态发生及疾病中的作用
Biochem Pharmacol. 2009 Feb 15;77(4):566-76. doi: 10.1016/j.bcp.2008.09.039. Epub 2008 Oct 14.
5
The aryl hydrocarbon receptor (AhR) inhibits vanadate-induced vascular endothelial growth factor (VEGF) production in TRAMP prostates.芳基烃受体(AhR)抑制TRAMP前列腺中钒酸盐诱导的血管内皮生长因子(VEGF)生成。
Carcinogenesis. 2008 May;29(5):1077-82. doi: 10.1093/carcin/bgn069. Epub 2008 Mar 20.